Trinbelimab 150mcg/mL Injection$62.00
1–9 boxes
$62.00 each
10–24 boxes
8% off
25+ boxes
10% off
Trinbelimab 150mcg/mL Injection
SKU GME1034Product Introduction
Trinbelimab 150mcg/mL is a recombinant anti-D antibody used for Rh prophylaxis after selected early-pregnancy sensitising events in an unsensitised Rh-negative woman. Preventing an anti-D immune response can help protect a future Rh-positive pregnancy from haemolytic disease.
How to use
A doctor or nurse gives the 150mcg dose into the deltoid muscle. This lower-dose presentation is used after selected actual or threatened pregnancy losses up to 12 weeks, with administration within 72 hours of exposure when prophylaxis is indicated. It is not given intravenously or to the newborn.
How it works
Trinbelimab binds the Rh-D antigen on fetal red blood cells that enter the mother's circulation. Their removal helps prevent the mother's immune system from developing a lasting anti-D antibody response.
Side effects
Pain, redness, warmth or swelling at the injection site may occur. Fever, flushing, headache or chills are also possible. Hives with facial swelling, wheezing or faintness can indicate a severe allergic reaction and need emergency treatment.
Important information
Rh-D blood group and an antibody screen determine whether prophylaxis is suitable. It does not reverse sensitisation once immune anti-D antibodies have developed. Keep refrigerated at 2-8 degrees C and do not freeze. Tell the maternity team about previous severe reactions to immunoglobulins.
Uses
- Rh-D prophylaxis after selected early-pregnancy sensitising events in an unsensitised Rh-negative woman.
Benefits
Reduces the chance of a maternal immune response that could destroy an Rh-positive baby's red blood cells. It provides passive protection without requiring the mother to produce her own anti-D antibodies.
Does this injection treat an infection?
No. Its purpose is to prevent an immune reaction to Rh-positive red blood cells, not to treat bacteria or viruses.
Is it still needed after birth if an antenatal dose was given?
An Rh-positive newborn can expose the mother to additional red blood cells during delivery. Postnatal prophylaxis can therefore still be needed after an antenatal dose.
What is the difference between the 150mcg and 300mcg presentations?
They contain different amounts of anti-D antibody. Pregnancy stage and the sensitising event determine the amount required; the smaller presentation is not automatically a substitute for the larger one.
What happens if more than 72 hours have passed?
Contact the maternity team promptly rather than assuming protection is no longer possible. They can assess the exposure, antibody results and whether delayed prophylaxis may still help.
Rh-D antigen: a protein on the surface of Rh-positive red blood cells; Alloimmunisation: development of antibodies against another person's red-cell antigens; Passive immunity: protection supplied by administered antibodies; Indirect Coombs test: a blood test for antibodies against red blood cells; Fetomaternal haemorrhage: passage of fetal blood into the mother's circulation; AR: Trinbelimab 150mcg/mL حقن; FR: Trinbelimab 150mcg/mL solution injectable; PT: Trinbelimab 150mcg/mL solução injetável; ES: Trinbelimab 150mcg/mL solución inyectable; RU: Trinbelimab 150mcg/mL раствор для инъекций; ID: Trinbelimab 150mcg/mL injeksi; VI: Trinbelimab 150mcg/mL thuốc tiêm; MS: Trinbelimab 150mcg/mL suntikan; TL: Trinbelimab 150mcg/mL iniksyon; ZH-SG: Trinbelimab 150mcg/mL 注射剂